Literature DB >> 6225476

Current status of high dose progestin treatment in advanced breast cancer.

W Mattsson.   

Abstract

Progestins, especially high dose medroxyprogesterone acetate, are receiving renewed attention in treatment of advanced breast cancer. The trials reviewed here indicate that such regimens may be as effective as tamoxifen in postmenopausal unselected cases, and that they may be effective as second-line treatment in patients resistant to tamoxifen and/or to cytotoxic chemotherapy.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6225476     DOI： 10.1007/bf01803566

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN： 0167-6806            Impact factor:   4.872


  10 in total

1.  High dose medroxyprogesterone-acetate treatment in advanced mammary carcinoma. A phase II investigation.

Authors:  W Mattsson
Journal:  Acta Radiol Oncol Radiat Phys Biol       Date:  1978

Review 2.  Tamoxifen in advanced breast cancer.

Authors:  H Mouridsen; T Palshof; J Patterson; L Battersby
Journal:  Cancer Treat Rev       Date:  1978-09       Impact factor: 12.111

3.  High-dose medroxyprogesterone acetate in breast cancer resistant to endocrine and cytotoxic therapy.

Authors:  M De Lena; C Brambilla; P Valagussa; G Bonadonna
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

Review 4.  Treatment of advanced breast cancer with progestins.

Authors:  J Løber; C Rose; M Salimtschik; H T Mouridsen
Journal:  Acta Obstet Gynecol Scand Suppl       Date:  1981

5.  [Use of high doses of medroxyprogesterone acetate in the palliative treatment of advanced breast cancer. Clinical experience with 44 cases].

Authors:  D Amadori; A Ravaioli; F Barbanti
Journal:  Minerva Med       Date:  1977-12-01       Impact factor: 4.806

6.  A possible new approach to the treatment of metastatic breast cancer: massive doses of medroxyprogesterone acetate.

Authors:  F Pannuti; A Martoni; G R Lenaz; E Piana; P Nanni
Journal:  Cancer Treat Rep       Date:  1978-04

7.  Medroxyprogesterone acetate (MPA) plasma levels after oral and intramuscular administration in a long-term study.

Authors:  I Hesselius; E D Johansson
Journal:  Acta Obstet Gynecol Scand Suppl       Date:  1981

8.  A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer.

Authors:  R J Santen; T J Worgul; E Samojlik; A Interrante; A E Boucher; A Lipton; H A Harvey; D S White; E Smart; C Cox; S A Wells
Journal:  N Engl J Med       Date:  1981-09-03       Impact factor: 91.245

9.  High dose medroxyprogesterone acetate (MPA) treatment in metastatic carcinoma of the breast: a dose-response evaluation.

Authors:  G R Cuna; A Calciati; M R Strada; C Bumma; L Campio
Journal:  Tumori       Date:  1978-04-30

Review 10.  High-dose medroxyprogesterone acetate (MPA) treatment in advanced breast cancer. A review.

Authors:  F Ganzina
Journal:  Tumori       Date:  1979-10-31
  10 in total
  5 in total

1.  CAF versus CAF plus Medroxyprogesterone Acetate for Treatment of Liver Metastases of Breast Cancer.

Authors: 
Journal:  Breast Cancer       Date:  1995-04-30       Impact factor: 4.239

Review 2.  Deciphering the divergent roles of progestogens in breast cancer.

Authors:  Jason S Carroll; Theresa E Hickey; Gerard A Tarulli; Michael Williams; Wayne D Tilley
Journal:  Nat Rev Cancer       Date:  2016-11-25       Impact factor: 60.716

3.  Growth inhibition of 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors by controlled-release low-dose medroxyprogesterone acetate.

Authors:  S Li; M Lepage; Y Mérand; A Bélanger; F Labrie
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

4.  Controlled release low dose medroxyprogesterone acetate (MPA) inhibits the development of mammary tumors induced by dimethyl-benz(a) anthracene in the rat.

Authors:  F Labrie; S Li; A Bélanger; J Côté; Y Mérand; M Lepage
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

5.  Androgen and glucocorticoid receptor-mediated inhibition of cell proliferation by medroxyprogesterone acetate in ZR-75-1 human breast cancer cells.

Authors:  R Poulin; D Baker; D Poirier; F Labrie
Journal:  Breast Cancer Res Treat       Date:  1989-03       Impact factor: 4.872
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.